Veradermics
MANE | NYSE
$139.69
-$4.16 (-2.89%)
At close: Oct 30, 2026, 4:00 PM ET
$140.56
+$0.87 (+0.62%)
Pre-market:
Nov 2, 2026, 7:02 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a |
Operating Income | -29.55M | -29.86M | -23.01M | -20.35M | -5.97M |
Interest Income | 4.84M | 2.48M | 906K | 71K | 209K |
Pretax Income | -23.5M | -27.23M | -21.85M | -20.1M | -5.66M |
Net Income | -23.5M | -27.23M | -21.85M | -20.1M | -5.66M |
Selling & General & Admin | 10.95M | 8.94M | 4.82M | 2.25M | 1.02M |
Research & Development | 18.61M | 20.93M | 18.19M | 18.1M | 4.95M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 29.55M | 29.86M | 23.01M | 20.35M | 5.97M |
Interest Expense | n/a | n/a | 532K | n/a | 292K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.55M | 29.86M | 23.01M | 20.35M | 5.97M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 40.44M | 37.34M | 37.34M | n/a | 201.33M |
Shares Outstanding (Diluted) | 40.44M | 37.34M | 37.34M | n/a | 201.33M |
EPS (Basic) | -0.58 | -0.80 | -0.76 | n/a | -0.03 |
EPS (Diluted) | -0.58 | -0.80 | -0.76 | n/a | -0.03 |
EBITDA | -29.55M | -27.23M | -21.32M | -19.16M | -5.37M |
EBIT | -29.55M | -27.23M | -21.32M | -19.16M | -5.37M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MANE